Technology
Evogene Reports Second Quarter 2024 Financial Results
Published
1 month agoon
By
Conference call and webcast: today, August 22, 2024, 9:00 am ET
Financial and Business Highlights:
H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023.Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra’s initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million.H1 2024 loss $9.8M, down from $14.8M in H1 2023; Q2 2024 loss $6.0M, down from $7.8M in Q2 2023.Projected 2024 cash usage (excl. Biomica & Lavie Bio) $8.0M, down 36% from $12.5M in 2023.Implemented a 10:1 reverse stock split during July 2024.
Casterra:
Received a $440K order for castor seeds from an existing customer for a new African country.Completed a successful castor seed season in Brazil, with shipments planned for Q3 2024.Seeds produced in Brazil and Africa in 2024, are anticipated to meet existing orders totaling approximately $8.4M.
Biomica:
Promising Phase 1 results for BMC128 with nivolumab in RCC, NSCLC, and melanoma, presented at ASCO 2024.
Lavie Bio:
A significant milestone achieved in ICL collaboration, developing yield-increasing bio-stimulants for row crops under extreme weather conditions by leveraging AI to identify over a dozen novel microbial candidates.Announced commercial expansion of Yalos™ bio-inoculant to winter wheat.
REHOVOT, Israel, Aug. 22, 2024 /PRNewswire/ — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the second quarter period ended June 30, 2024.
Mr. Ofer Haviv, Evogene’s President and CEO, stated: “In our vision, we see Evogene as a pioneering company for creating groundbreaking life-science products, to improve life quality and longevity. During the past years we developed three innovative AI tech-engines addressing the main development challenges of products rooted in microbes, small molecules and genomics. Our AI tech-engines were structured to be compatible with the tremendous potential of various market segments and not limited to only one specific segment.
“In order to capture the value of our AI tech-engines, our business strategy is to establish diverse collaborative partnerships through licensing or collaboration, with expert partners in specific fields that complement our technology. Together, we’ll develop novel products, aiming for full or partial ownership upon project completion. This approach maximizes the potential of our AI tech-engines, while aiming to reduce financial and development risks. Today, Evogene has 4 subsidiaries, each focusing on a different market segment, and in addition, Evogene has diverse engagements with leading companies in additional market segments, not covered by our subsidiaries.
“I am very pleased to share with you the main achievements made by Evogene’s subsidiaries from the last report of our financial results.”
Casterra Ag Ltd. – focuses on developing an integrated solution to enable large-scale commercial cultivation of castor to address the global demand for stable castor oil supply, mainly for the biodiesel industry. Casterra is utilizing Evogene’s GeneRator AI tech engine to direct and accelerate the development of its unique elite castor seed varieties.
On June 25, Casterra announced receiving a $440K purchase order to supply castor seeds to a new African country in 2024. This order from an existing customer expands Casterra’s operations and strengthens its position in the bio-fuel market.On July 31, Casterra announced the successful completion of its castor seed growing and harvesting season in Brazil, with shipments planned for the third quarter of 2024. Additionally, the castor harvest season in Africa has begun as scheduled.Castor seeds produced in 2024 in both Brazilian and African territories are expected to enable Casterra to meet all its existing orders, amounting to approximately $8.4M, with completion anticipated by the end of this year.
Lavie Bio Ltd. – a leading ag-biologicals company that develops microbiome-based, computational-driven novel bio-stimulant and bio-pesticide products, utilizing Evogene’s MicroBoost AI tech-engine.
On July 2, Lavie Bio announced the commercial expansion of its bio-inoculant Yalos™ to winter wheat following successful trials, with sales starting across the US for the 2024-2025 season, effectively doubling its market potential.On July 22, 2024, Lavie Bio announced a milestone in its collaboration with ICL in developing bio-stimulant solutions for row crops facing extreme weather conditions by leveraging AI to identify over a dozen novel microbes within 12 months.Lavie Bio’s pipeline is advancing according to plan, with field trials initiated in Q2 in most of the company’s programs, following successful optimization processes. Results are expected during Q4.
Biomica Ltd. – a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, utilizing Evogene’s MicroBoost AI tech-engine.
On May 23, positive safety and tolerability data for BMC128 was published. 72% of the patients treated have exhibited clinical benefits. 55% of patients showed sustained clinical benefit, with notable durations of effect (more than 24 months).These clinical results were presented at the prestigious 2024 ASCO annual conference in June.We look forward to continuing to evaluate BMC128’s beneficial activity in subsequent phases of clinical development.
Financial Highlights:
Cash Position: As of June 30, 2024, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $20.9 million. This amount does not include $8.4 million of expected payments for the open purchase orders of Casterra. The consolidated cash usage during the second quarter of 2024 was approximately $5.7 million. Excluding Lavie Bio and Biomica, Evogene and its other subsidiaries used approximately $2.7 million in cash during the second quarter of 2024. Projected cash usage for 2024, excluding Lavie Bio and Biomica, is expected to be around $8.0 million, marking a notable 36% decrease from approximately $12.5 million in 2023.
Revenue: Revenues for the first half of 2024 were approximately $5.1 million, a significant increase from $1.3 million in the same period the previous year. This growth was primarily driven by revenues recognized from Lavie Bio’s licensing agreement with Corteva and AgPlenus’s new collaboration with Bayer. Revenues for the second quarter of 2024 were approximately $0.9 million, compared to approximately $0.7 million in the same period the previous year. The increase was mainly attributable to increased revenue in Lavie Bio.
Evogene anticipates continued revenue growth in the second half of 2024 compared to the previous year, mainly based on Casterra’s forecast for seed-order supply.
R&D Expenses: Research and development expenses, net of non-refundable grants, for the first half of 2024 were approximately $8.8 million, a decrease from $10.2 million in the first half of 2023. The decrease in expenses is mainly due to the cease of Canonic’s activities and a decrease in certain development expenses in Biomica as compared to the same period the previous year. Research and development expenses, net of non-refundable grants, for the second quarter of 2024 were approximately $4.0 million, and decreased significantly as compared to approximately $5.4 million in the same period in the previous year. The decrease is mainly attributable to decreased expenses in Canonic and Biomica, as mentioned above.
Sales and Marketing Expenses: Sales and Marketing expenses for the first half of 2024 were approximately $1.9 million, a slight increase from approximately $1.7 million in the same period in the previous year. The increase is mainly attributable to increased sales and marketing activities in Casterra during the first half of 2024 as compared to the same period in 2023. Sales and Marketing expenses for the second quarter of 2024 were approximately $0.9 million and remained stable as compared to approximately $0.9 million in the same period in the previous year.
General and Administrative Expenses: General and administrative expenses for the first half of 2024 decreased slightly to approximately $3.2 million from approximately $3.3 million in the same period last year. General and administrative expenses for the second quarter of 2024 decreased to approximately $1.5 million compared to approximately $1.8 million in the same period of the previous year, mainly due to decreased non-cash compensation and salary related expenses in Lavie Bio and Biomica, respectively, in the second quarter of 2024.
Other Expenses: The decision to cease Canonic’s operations in the first half of 2024 resulted in other expenses of approximately $0.5 million, mainly due to impairment of fixed assets in the first quarter of 2024.
Operating Loss: The operating loss for the first half of 2024 was approximately $10.2 million, a significant decrease from approximately $14.7 million in the same period of the previous year, mainly due to increased revenues as mentioned above. The operating loss for the second quarter of 2024 was approximately $6.1 million, a decrease from $7.9 million in the same period of the previous year, mainly due to decreased operating expenses as mentioned above.
Financing Income: Financing income, net for the first half of 2024 was $379 thousand, compared to financing expenses, net of $86 thousand in the same period of the previous year. This increase was primarily due to increased interest income and a revaluation of convertible SAFE. Financing income, net for the second quarter of 2024 was $138 thousand, compared to financing income, net of $144 thousand in the same period of the previous year.
Net Loss: The net loss for the first half of 2024 was approximately $9.8 million, compared to approximately $14.8 million in the same period last year. The $5.0 million decrease in net loss was primarily due to increased revenues, decreased operating expenses, partially offset by the one-time $0.5 million of other expenses, related to ceasing Canonic’s operations and an increase in financial income. The net loss for the second quarter of 2024 was approximately $6.0 million, compared to approximately $7.8 million in the same period last year. The $1.8 million decrease in net loss was primarily due to decreased operating expenses as mentioned above.
For the financial tables click here.
Conference Call & Webcast Details: Thursday, August 22, 2024. 9:00 AM EST 4:00 PM IDT
To join the Zoom conference, please register in advance here.
Or join via audio
Or, dial from the US: +15642172000, from Israel: +972 3 978 6688
Webinar ID: 842 8320 2980
More International numbers
Webcast & Presentation link available at:
https://evogene.com/investor-relations
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
Biomica Ltd. (www.biomicamed.com) – developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;Lavie Bio (www.lavie-bio.com) – developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;AgPlenus Ltd. (www.agplenus.com) – developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI;Casterra Ag (www.casterra.co) – developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “hopes” “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, “demonstrates” or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss Evogene’s strategy, Evogene’s ability to develop novel products, that Evogene’s strategy will result groundbreaking innovations and significant financial gains for Evogene, Casterra’s ability to supply all existing purchase orders by the end of 2024, Lavie Bio’s market potential, Lavie Bio’s pipeline advancement, Biomica’s BMC128’s future beneficial activity, and Evogene’s projected cash usage for 2024 and Evogene anticipated continued revenue growth in the second half of 2024. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel, and those risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
Evogene Investors Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
June 30,
December 31,
2024
2023
Unaudited
Audited
CURRENT ASSETS:
Cash and cash equivalents
$ 9,484
$ 20,772
Short-term bank deposits
11,424
10,291
Trade receivables
376
357
Other receivables and prepaid expenses
3,696
2,973
Inventories
794
76
25,774
34,469
LONG-TERM ASSETS:
Long-term deposits and other receivables
30
28
Investment accounted for using the equity method
100
–
Right-of-use-assets
729
980
Property, plant and equipment, net
1,650
2,455
Intangible assets, net
12,685
13,169
15,194
16,632
$ 40,968
$ 51,101
CURRENT LIABILITIES:
Trade payables
$ 957
$ 1,785
Employees and payroll accruals
2,333
2,537
Lease liability
558
853
Liabilities in respect of government grants
681
388
Deferred revenues and other advances
548
362
Other payables
816
1,019
5,893
6,944
LONG-TERM LIABILITIES:
Lease liability
252
285
Liabilities in respect of government grants
4,247
4,426
Deferred revenues and other advances
244
393
Convertible SAFE
10,392
10,368
15,135
15,472
SHAREHOLDERS’ EQUITY:
Ordinary shares of NIS 0.2 par value:
Authorized − 15,000,000 ordinary shares; Issued and outstanding − 5,096,760 shares as of
June 30, 2024, and 5,079,313 (*) shares as of December 31, 2023
287
286
Share premium and other capital reserve
269,648
269,353
Accumulated deficit
(266,868)
(257,586)
Equity attributable to equity holders of the Company
3,067
12,053
Non-controlling interests
16,873
16,632
Total equity
19,940
28,685
$ 40,968
$ 51,101
(*) Shares and per share amounts have been retroactively adjusted to reflect the reverse stock split
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS
U.S. dollars in thousands (except share and per share amounts)
Six months ended
June 30,
Three months ended
June 30,
Year ended
December 31,
2024
2023
2024
2023
2023
Unaudited
Audited
Revenues
$ 5,104
$ 1,295
$ 914
$654
$ 5,640
Cost of revenues
847
783
537
461
1,692
Gross profit
4,257
512
377
193
3,948
Operating expenses:
Research and development, net
8,817
10,169
4,016
5,369
20,777
Sales and marketing
1,920
1,728
928
928
3,611
General and administrative
3,184
3,312
1,530
1,797
6,068
Other expenses
524
–
5
–
–
Total operating expenses, net
14,445
15,209
6,479
8,094
30,456
Operating loss
(10,188)
(14,697)
(6,102)
(7,901)
(26,508)
Financing income
667
699
260
391
1,486
Financing expenses
(288)
(785)
(122)
(247)
(965)
Financing income (expenses), net
379
(86)
138
144
521
Share of loss from equity accounted investment
(20)
–
(20)
–
–
Loss before taxes on income
(9,829)
(14,783)
(5,984)
(7,757)
(25,987)
Taxes on income (tax benefit)
1
(24)
1
21
(33)
Loss
$ (9,830)
$ (14,759)
$ (5,985)
$(7,778)
$ (25,954)
Attributable to:
Equity holders of the Company
$ (9,282)
$ (13,294)
$ (5,419)
$ (7,023)
$ (23,879)
Non-controlling interests
(548)
(1,465)
(566)
(755)
(2,075)
$ (9,830)
$ (14,759)
$ (5,985)
$(7,778)
$ (25,954)
Basic and diluted loss per share, attributable to equity holders of
the Company (*)
$ (1.82)
$ (3.18)
$ (1.06)
$(1.68)
$ (5.20)
Weighted average number of shares used in computing basic and
diluted loss per share (*)
5,087,029
4,177,554
5,090,993
4,185,242
4,589,386
(*) Shares and per share amounts have been retroactively adjusted to reflect the
reverse stock split
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Six months ended
June 30,
Three months ended
June 30,
Year ended
December 31,
2024
2023
2024
2023
2023
Unaudited
Audited
Cash flows from operating activities
Loss
$ (9,830)
$ (14,759)
$ (5,985)
$ (7,778)
$ (25,954)
Adjustments to reconcile loss to net cash used in operating activities:
Adjustments to the profit or loss items:
Depreciation
800
807
374
406
1,641
Amortization of intangible assets
484
481
239
241
971
Share-based compensation
999
1,219
460
801
1,877
Revaluation of convertible SAFE
24
220
49
26
254
Net financing expenses (income)
(222)
6
(28)
60
(666)
Loss (gain) from sale of property, plant and equipment
524
(26)
5
–
(26)
Share of loss from equity accounted investment
20
–
20
–
–
Taxes on income (tax benefit)
1
(24)
1
21
(33)
2,630
2,683
1,120
1,555
4,018
Changes in asset and liability items:
Decrease (increase) in trade receivables
(19)
170
163
72
(9)
Decrease (increase) in other receivables
(725)
84
(546)
375
(1,445)
Decrease (increase) in inventories
(718)
317
(78)
342
490
Decrease in deferred taxes
–
–
–
–
94
Increase (decrease) in trade payables
(762)
26
(77)
(95)
742
Increase (decrease) in employees and payroll accruals
(204)
172
(99)
117
550
Increase (decrease) in other payables
(214)
(162)
(153)
297
(534)
Increase (decrease) in deferred revenues and other advances
(84)
(73)
(13)
(81)
(288)
(2,726)
534
(803)
1,027
(400)
Cash received (paid) during the period for:
Interest received
402
283
231
145
905
Interest paid
(41)
(66)
(18)
(30)
(115)
Taxes paid
–
(10)
–
(10)
(31)
Net cash used in operating activities
$ (9,565)
$ (11,335)
$ (5,455)
$ (5,091)
$ (21,577)
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Six months ended
June 30,
Three months ended
June 30,
Year ended
December 31,
2024
2023
2024
2023
2023
Unaudited
Audited
Cash flows from investing activities:
Purchase of property, plant and equipment
$ (172)
(483)
(31)
(124)
$ (785)
Proceeds from sale of marketable securities
–
6,924
–
6,287
6,924
Purchase of marketable securities
–
(503)
–
(503)
(503)
Proceeds from sale of property, plant and equipment
10
26
–
–
26
Withdrawal from (investment in) bank deposits, net
(990)
(13,560)
3,241
(13,560)
(10,200)
Net cash provided by (used in) investing activities
$ (1,152)
$ (7,596)
$ 3,210
$ (7,900)
$ (4,538)
Cash flows from financing activities:
Issuance of a subsidiary preferred shares to non-controlling interests
–
9,523
–
9,523
9,523
Proceeds from issuance of ordinary shares, net of issuance expenses
86
336
83
68
8,449
Repayment of lease liability
(462)
(413)
(231)
(207)
(836)
Proceeds from government grants
–
1,089
–
1,063
1,089
Repayment of government grants
(142)
(35)
(3)
–
(73)
Net cash provided by (used in) financing activities
(518)
10,500
(151)
10,447
18,152
Exchange rate differences – cash and cash equivalent balances
(53)
(316)
(35)
(223)
(245)
Decrease in cash and cash equivalents
(11,288)
(8,747)
(2,431)
(2,767)
(8,208)
Cash and cash equivalents, beginning of the period
20,772
28,980
11,915
23,000
28,980
Cash and cash equivalents, end of the period
$ 9,484
$ 20,233
$ 9,484
$ 20,233
$ 20,772
Significant non-cash activities
Acquisition of property, plant and equipment
$ 15
$ 90
$ 15
$ 21
$ 81
Investment in equity-accounted investee with corresponding
deferred revenues
$ 120
$ –
$ –
$ –
$ –
Increase of right-of-use asset recognized with corresponding
lease liability
$ 184
$ 135
$ 54
$ 64
$ 194
View original content:https://www.prnewswire.com/news-releases/evogene-reports-second-quarter-2024-financial-results-302228513.html
SOURCE Evogene
You may like
Technology
DeepL unveils industry-first Glossary Generator to solve business communication and brand consistency challenges
Published
6 mins agoon
September 23, 2024By
Enhanced DeepL glossary functionality – including new glossary generator, expanded language support and more – will boost global business translations, saving time, effort, and costs
COLOGNE, Germany, Sept. 23, 2024 /PRNewswire/ — DeepL, a leading global Language AI company, today announced several updates to its glossary feature, which is a powerful tool that enhances translation consistency and accuracy by enabling professionals and companies to personalize translations for specific terms. The tool now offers the industry’s first smart glossary generator, which helps simplify and speed up the process of creating glossaries for translations. Glossary is also available in several new languages and within DeepL’s browser extensions and integrations, fitting seamlessly into existing workflows to offer an even more accessible and smooth user experience across the web and applications like Google Workspace and Microsoft 365.
“AI-powered translations are essential for businesses looking to overcome language barriers in today’s increasingly connected world, and DeepL’s powerful glossary tool takes this a step further by ensuring translations are personalized to a company’s unique phrases and needs,” said Christopher Osborne, VP of Product, DeepL. “We’re always looking for ways to improve the DeepL experience and drive even more value and ROI for 100,000+ customers worldwide, and these new capabilities make our glossary even more efficient, accessible and user-friendly – empowering teams to achieve the customization and consistency they are looking for, while minimising time spent on costly alternatives like manual translations or find-and-replace tools.”
For global businesses aiming to drive revenue growth, investing in brand consistency across all communications and languages is essential to ensure that every message—whether technical terminology, product names, or branded terms—resonates clearly with teams, customers, and markets worldwide. Consistent branding has been proven to increase revenue by 20% or more[1] and enhance visibility by 3 to 4 times[2] – however, maintaining this consistency can be expensive and complex. DeepL’s glossary tool simplifies this process, helping businesses and professionals easily create and scale high-quality, consistent multilingual communications across teams. With glossary, companies can create and manage custom translation glossaries to ensure that specific words or phrases are translated consistently according to their unique terminology.
DeepL’s glossary now offers the following expanded capabilities:
The industry’s first smart, AI-powered glossary generator: DeepL’s new glossary generator is a first-of-its-kind tool enabling teams to create custom translation glossaries with a simple file upload. Previously translated files can be leveraged to generate entries for personalized DeepL glossaries, reducing the need for manual work and significantly enhancing efficiency, enabling teams to facilitate more consistent communication at scale.Expanded glossary language functionality: Glossary now supports Korean, Danish, Swedish, Norwegian, and Romanian translations, bringing the total number of languages to 16. This allows for more precise and nuanced translations across a wider range of linguistic contexts, helping businesses reach a broader audience.More convenient access across DeepL platforms: Users are now able to access and apply the glossary directly within the DeepL browser extensions for Chrome and Edge, enabling consistent translations across the web, including Google Workspace applications. Furthermore, the glossary can now also be applied directly within DeepL for Microsoft 365 integrations, including Word, Outlook, and PowerPoint. Additionally, the glossary can be accessed through DeepL’s web browser, desktop apps, and API.
Unlike other find-and-replace tools, DeepL’s glossary excels with its advanced contextual understanding and ability to process complex grammatical elements—such as case, gender, and tense—to deliver nuanced, natural-sounding translations. This results in substantial productivity gains, largely due to the time saved in post-editing. Blind tests with language experts show that DeepL reduces post-editing time by 30% compared to Google Translate and 20% compared to Chat GPT-4. Furthermore, DeepL requires significantly fewer edits, with Google Translate and Chat GPT-4 needing two to three times as many feedback rounds.
Glossary with DeepL Pro also offers enhanced data security, including proprietary data centers, the highest level of certification and compliance standards (ISO 27001 certification, GDPR/SOC 2 type 2 compliance), data encryption, and a commitment to never using Pro customer data to train models.
DeepL’s glossary generator is now available to Pro Advanced and Ultimate subscribers with support for TMX/DOCX/PDF files. It is initially available for glossaries in German, Spanish, Japanese, Italian, French, and Russian (to and from English), with more languages coming soon.
Learn more about DeepL Pro and try out glossary yourself here.
About DeepL
DeepL is on a mission to break down language barriers for businesses everywhere. Over 100,000 businesses and governments and millions of individuals in 228 global markets trust DeepL’s Language AI platform for human-like translation and better writing. Designed with enterprise security in mind, companies around the world leverage DeepL’s AI solutions that are specifically tuned for language to transform business communications, expand markets, and improve productivity. Founded in 2017 by CEO Jaroslaw (Jarek) Kutylowski, DeepL today has over 900 passionate employees and is supported by world-renowned investors including Benchmark, IVP, and Index Ventures.
[1] Marq, “2021 Brand Consistency Report”
[2] Demand Metric x Lucid Press, “Impact of Brand Consistency” Report, 2016
View original content:https://www.prnewswire.com/apac/news-releases/deepl-unveils-industry-first-glossary-generator-to-solve-business-communication-and-brand-consistency-challenges-302254939.html
SOURCE DeepL
Technology
Agoda: Chinese Travelers Post a 137% Increase in International Searches for Upcoming Golden Week
Published
6 mins agoon
September 23, 2024By
SINGAPORE, Sept. 23, 2024 /PRNewswire/ — Digital travel platform Agoda has revealed a 137% year-over-year increase in international accommodation searches from China for the upcoming Golden Week. China’s second Golden Week of the year takes place from 1 to 7 October.
Agoda’s accommodation search data reveals a shift in Chinese travelers’ preferences for Golden Week. Last year, the top five outbound destinations were Tokyo, Seoul, Osaka, Kyoto, and Bangkok, respectively. This year, Seoul has emerged as the number one destination, leapfrogging Tokyo. Bali is a new entry in the top five and takes third place. Bangkok and Osaka continue to be among the most searched destinations and complete the ranking in fourth and fifth, respectively.
Taking place from 1 – 7 October this year, Golden Week is a prime travel period for Chinese families looking to take advantage of the week-long break. Golden Weeks are celebrated twice a year in China, around Lunar New Year and China’s National Day.
Top Outbound Destinations for Golden
Week 2024
(Based on Agoda’s accommodation search data)
1. Seoul, South Korea
2. Tokyo, Japan
3. Bali, Indonesia
4. Bangkok, Thailand
5. Osaka, Japan
Andrew Smith, Senior Vice President, Supply at Agoda said, “The increase in outbound travel searches for China’s Golden Week suggests a growing confidence among Chinese citizens to explore international travel. It’s great to see destinations close to China’s east coast like Seoul and Osaka featured in the rank, as well as holiday favorites Bangkok and Bali further south. With the unique advantage of its ‘Asia hotels’ network, Agoda is committed to helping Chinese customers to experience the rest of Asia for less with its great value deals.”
Agoda continues to support travelers by offering over 4.5 million holiday properties globally, more than 130,000 flight routes, and over 300,000 activities, all of which can be conveniently combined in the same booking. For more information on travel options during China’s Golden Week, visit agoda.com or download the Agoda app.
About Agoda
Agoda, a digital travel platform, helps anyone see the world for less with its great value deals on a global network of 4.5M hotels and holiday properties worldwide, plus flights, activities, and more. Agoda.com and the Agoda mobile app are available in 39 languages and supported by 24/7 customer support.
Headquartered in Singapore, Agoda is part of Booking Holdings (Nasdaq: BKNG) and employs more than 6,900 staff in 25 markets, dedicated to leveraging best-in-class technology to make travel even easier.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agoda-chinese-travelers-post-a-137-increase-in-international-searches-for-upcoming-golden-week-302254966.html
SOURCE Agoda
Technology
AECOM supports the Highways Department in winning the Hong Kong Institute of Surveyors Awards for innovative road safety technology
Published
6 mins agoon
September 23, 2024By
HONG KONG, Sept. 23, 2024 /PRNewswire/ — AECOM, the world’s trusted infrastructure consulting firm, today announced that a Road Defect Detection System (RDDS) technology it has developed in partnership with the Highways Department of HKSAR Government (HyD) has secured two prestigious awards from the Hong Kong Institute of Surveyors (HKIS). This RDDS project, under part of the award-winning topic “Sustainability Strategy in Road and Tree Inspection by Advanced Geo-spatial Technology,” integrates advanced geographic information system (GIS) and artificial intelligence technologies to automatically detect road defects. The new technology aims to streamline the road inspection process, improving maintenance efficiency, effectively allocating resources and helping ensure public safety.
“AECOM is dedicated to delivering innovative solutions that meet our clients’ specific needs and address their complex challenges. From deploying the world’s largest tunnel boring machine for the Tuen Mun-Chek Lap Kok Link project to integrating GeoAI in our Road Defect Detection System, we harness emerging technologies to support the Highways Department in delivering landmark projects that span tunnels, bridges, highways, and now digital solutions,” said Ian Chung, chief executive of AECOM’s Asia region.
The jointly developed RDDS technology responds to the pressing need to effectively survey Hong Kong’s vast and complex road network. To provide a superior alternative to traditional inspection methods, the AECOM and HyD teams developed an approach that automatically detects defects from road images captured by a vehicle-based camera system.
Integrating the two organizations’ geospatial expertise, the technology uses AI to identify cracks and discolored road markings from road images, which can then be viewed on a web application platform that integrates data such as quantity, location, and severity for engineers to review and assess. The multi-step system simplifies the inspection process and allows for more efficient resource allocation — bringing greater efficiency to HyD’s road maintenance work and supporting a safer road network.
The HKIS honored the technology with the Innovative Surveying Award, which commends industry participants for outstanding project quality in innovative surveying technology, and the Post-occupation Category Grand Award, which recognizes the surveyors’ efforts in enhancing work efficiency and precision through innovative technology at post-occupation stage.
The HKIS Awards aim to recognize the outstanding achievements of Hong Kong surveyors. The awards align with the Sustainable Development Goals set by the United Nations, affirming surveyors’ exceptional accomplishments in sustainable development projects and their contributions to improving environmental outcomes and promoting a sustainable future for Hong Kong.
For more details about the project, please visit here.
About AECOM
AECOM is the world’s trusted infrastructure consulting firm, delivering professional services throughout the project lifecycle – from advisory, planning, design and engineering to program and construction management. On projects spanning transportation, buildings, water, new energy and the environment, our public- and private-sector clients trust us to solve their most complex challenges. Our teams are driven by a common purpose to deliver a better world through our unrivaled technical and digital expertise, a culture of equity, diversity and inclusion, and a commitment to environmental, social and governance priorities. AECOM is a Fortune 500 firm and its Professional Services business had revenue of US$14.4 billion in fiscal year 2023. See how we are delivering sustainable legacies for generations to come at www.aecom.com/hk/.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/aecom-supports-the-highways-department-in-winning-the-hong-kong-institute-of-surveyors-awards-for-innovative-road-safety-technology-302253074.html
SOURCE AECOM
DeepL unveils industry-first Glossary Generator to solve business communication and brand consistency challenges
Agoda: Chinese Travelers Post a 137% Increase in International Searches for Upcoming Golden Week
AECOM supports the Highways Department in winning the Hong Kong Institute of Surveyors Awards for innovative road safety technology
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Peloton Unveils Holiday 2022 Creative Campaign Highlighting How Motivation Transcends Beyond the Workout
These ’90s fashion trends are making a comeback in 2017
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market3 days ago
Feds end Bitcoin bandits’ luxury life fueled by $230M crypto scam
-
Near Videos3 days ago
[REDACTED] online hackathon workshop workshop with Calimero Network
-
Technology1 day ago
Summit of Whose Future? Girls Have the Answers: Leaders Must Listen
-
Coin Market5 days ago
Australia’s central bank launches 3-year program for wholesale CBDC
-
Coin Market2 days ago
Indian Supreme Court recovers YouTube account from XRP scammers
-
Near Videos22 hours ago
Near AI Tech Showcase recap Singapore Token2049
-
Technology4 days ago
Wintermute reports a 19x rise in crypto CFD volumes and becomes the first OTC desk to offer GMCI index trading
-
Technology5 days ago
New survey finds UAE emerging as a global tech hub for Asian talent